Sage Journals: Discover world-class research

Abstract

Aims: To explore psychotropic drug use in the general population and in particular among non-institutionalized persons with mental distress symptoms. Methods: A total of 14,139 women and 11,665 men participating in the Oslo Health Study or the Oppland/Hedmark Study 2000—2001 submitted a self-administered questionnaire on health status and drug use, lifestyle, and socioeconomic factors. Respondents using antidepressants, hypnotics, and/or anxiolytics during the last four weeks were defined as users. A high Hopkins Symptoms Checklist-10 score indicated mental distress. The 15% with the highest score in each gender and age group (adults: 30/40/45 years; elderly: 60 years) were studied. Results: The prevalence of antidepressant use among those with mental distress was, for women: adults 21%; elderly 30%; and for men, adults 15%; elderly 15%. These figures were nearly four times higher than in the general population. Not participating in the labour market was the main factor associated with use of antidepressants for subjects with mental distress: adult women (odds ratio (OR) 3.5; 95% confidence interval (CI) 2.5—5.0); elderly women (OR 5.2; CI 2.7—10.2); adult men (OR 4.7; CI 3.0—7.3); and elderly men (OR 2.9; CI 1.4—6.0). Use of analgesics was the main factor associated with use of anxiolytics/hypnotics: adult women (OR 2.4; CI 1.7—3.4); elderly women (OR 2.3; CI 1.4—3.8); adult men (OR 2.1; CI 1.3—3.3); and elderly men (OR 3.4; CI 1.9—6.0). Conclusions: Among individuals with mental distress, not participating in the labour market and regular use of analgesics were the main factors associated with use of psychotropics in both genders regardless of age.

Keywords

Analgesics antidepressants anxiolytics employment status hypnotics mental distress symptoms psychotropic drugs population-based

Get full access to this article

View all access options for this article.

References

Alonso J. , Angermeyer MC , Bernert S. , Bruffaerts R. , Brugha TS , Bryson H. , et al. Psychotropic drug utilization in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand 2004;(Suppl):55—64.

Rønning M , editor. Drug consumption in Norway 2000— 2004. [Legemiddelforbruket i Norge 2000—2004: en statistisk fremstilling av legemiddelforbruket i Norge for årene 2000—2004 basert på omsetning av legemidler fra legemiddelgrossister til apotek, sykehus og dagligvarehandel] Oslo: Norwegian Institute of Public Health; 2005.

Rønning M. Coding and classification in drug statistics: From national to global application. Nor J Epidemiology 2001;11:37—40.

Health Statistics in the Nordic Countries 2001 [Helsestatistik for de nordiske lande 2001]. 66:2003. København, Nordic Medico Statistical Committee (NOMESCO); 2003.

Bramness JG , Hausken AM , Sakshaug S. , Skurtveit S. , Ronning M.

Prescription of selective serotonin reuptake inhibitors 1990—2004. [Forskrivning av selektive serotoninreopptakshemmere 1990—2004]

Tidsskr Nor Laegeforen 2005 ;125:2470—3.

Pallesen S. , Nordhus IH , Nielsen GH , Havik OE , Kvale G. , Johnsen BH , Skjotskift S. Prevalence of insomnia in the adult Norwegian population. Sleep 2001;24:771—9.

Bjorndal A. , Forsén L. En pille for alt som er ille? En analyse av psykofarmakaforbruket i Helseundersøkelsen i Nord-Trøndelag 1984—86 (English summary). Report no. 7. Oslo: Unit for Health Services Research, National Institute of Public Health; 1989.

Nielsen MW , Hansen EH , Rasmussen NK Patterns of psychotropic medicine use and related diseases across educational groups: National cross-sectional survey . Eur J Clin Pharmacol 2004;60:199—204.

Empereur F. , Baumann M. , Alla F. , Briancon S. Factors associated with the consumption of psychotropic drugs in a cohort of men and women aged 50 and over. J Clin Pharm Ther 2003;28:61—8.

10.

Ohayon MM , Lader MH Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J Clin Psychiatry 2002;63:817—25.

11.

Villaverde Ruiz ML , De la Fuente JA , Gracia MR , Agullar Garcia-Iturrospe E. Psychotropic and analgesic drugs consumption in general population in Tenerife Island. Eur J Psychiatry 2000;14:213—20.

12.

Blennow G. , Romelsjo A. , LeifmanH. , LeifmanA. , KarlssonG. Sedatives and hypnotics in Stockholm: Social factors and kinds of use. Am J Public Health 1994;84:242—6.

13.

Isacson D. , Haglund B. Psychotropic drug use in a Swedish community: The importance of demographic and socioeconomic factors. Soc Sci Med 1988 ;26:477—83.

14.

Tellnes G. , Bjorndal A. , Fugelli P. Psychotropic drug-users and non-users in general practice, I: A three-year retrospective study from an island community in northern Norway. Scand J Prim Health Care 1986;4:131—5.

15.

Grohmann R. , Engel RR , Geissler KH , Ruther E. Psychotropic drug use in psychiatric inpatients: Recent trends and changes over time — data from the AMSP study. Pharmacopsychiatry 2004;37(Suppl 1):S27—S38.

16.

Voirol P. , Robert PA , Meister P. , Oros L. , Baumann P. Psychotropic drug prescription in a psychiatric university hospital. Pharmacopsychiatry 1999 ;32:29—37.

17.

Marino S. Ill-health and social predictors of psychotropic drug prescription in general practice. Int J Soc Psychiatry 1993;39:167—76.

18.

Rundberg J. , Lidfeldt J. , Nerbrand C. , Samsioe G. , Romelsjo A. , Ojehagen A. Few middle-aged women with severe mental symptoms use psychotropic drugs: The Women's Health in Lund Area (WHILA) study. Scand J Public Health 2005;33:384—91.

19.

Strand BH , Dalgard OS , Tambs K. , Rognerud M. Measuring the mental health status of the Norwegian population: A comparison of the instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36). Nord J Psychiatry 2003;57:113—18.

20.

Selmer R. , Soegard AJ , Bjertness E. , Thelle D.

The Oslo Health Study: Reminding the non-responders — effects on prevalence estimates. Nor

J Epidemiol 2003;13:89—94.

21.

The Oslo Health Study. Main questionnaire. Available at http://www.fhi.no/dav/66091FDE33734FAB96849B26D9-F46333.pdf (accessed 17 January 2006).

22.

Furu K. , Skurtveit S. , Rosvold E.

Drug use questions in Norwegian health surveys: Response rate and agreement between specific and open-ended questions. Nor

J Epidemiol 2003;13:147—54.

23.

Derogatis LR , Lipman RS , Rickels K. , Uhlenhuth EH , Covi L. The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory. Behav Sci 1974;19:1—15.

24.

Hartikainen S. , Mantyselka P. , Louhivuori-Laako K. , Enlund H. , Sulkava R. Concomitant use of analgesics and psychotropics in home-dwelling elderly people — Kuopio 75+study. Br J Clin Pharmacol 2005 ;60:306—10.

25.

Zimmermann-Tansella C. , Donini S. , Ciommei AM , Siciliani O. Social factors associated with the use of psychotropic drugs: Alcohol abuse and minor psychiatric morbidity in the community . Acta Psychiatr Scand 1988;1:14—21.

26.

Van Dongen CJ Quality of life and self-esteem in working and nonworking persons with mental illness. Community Ment Health J 1996;32:535—48.

27.

Miguel RV Pain medicine: Why and when to call for the addictionologist and/or psychiatrist. Regional Anesthesia & Pain Management, 2005:221—7.

28.

Power JD , Perruccio AV , Badley EM Stress, depression and pain as mediators between chronic conditions and sleep problems. Am J Epidemiol 2005;161:S6.

29.

Søgaard A. , Selmer R. , Bjertness E. , Thelle D.

The Oslo Health Study: The impact of self-selection in a large, population-based survey. Int J Equity

Health 2004;3:3.

30.

Van den Brandt PA , Petri H. , Dorant E. , Goldbohm RA , Van de CS Comparison of questionnaire information and pharmacy data on drug use. Pharm Weekbl Sci 1991;13:91—6.

Psychotropic drug use among persons with mental distress symptoms: A population-based study in Norway

Abstract

Keywords

Get full access to this article

References